Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Non-Current Debt (2016 - 2021)

Arcadia Biosciences filings provide 7 years of Non-Current Debt readings, the most recent being $78000.0 for Q3 2021.

  • On a quarterly basis, Non-Current Debt fell 96.94% to $78000.0 in Q3 2021 year-over-year; TTM through Sep 2021 was $78000.0, a 96.94% decrease, with the full-year FY2020 number at $2.1 million, up 1867.29% from a year prior.
  • Non-Current Debt hit $78000.0 in Q3 2021 for Arcadia Biosciences, down from $87000.0 in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $23.1 million in Q1 2017 to a low of $78000.0 in Q3 2021.
  • Median Non-Current Debt over the past 4 years was $130000.0 (2020), compared with a mean of $4.7 million.
  • Biggest five-year swings in Non-Current Debt: skyrocketed 2154.87% in 2020 and later plummeted 96.94% in 2021.
  • Arcadia Biosciences' Non-Current Debt stood at $21.1 million in 2017, then tumbled by 99.49% to $107000.0 in 2019, then skyrocketed by 1867.29% to $2.1 million in 2020, then crashed by 96.29% to $78000.0 in 2021.
  • The last three reported values for Non-Current Debt were $78000.0 (Q3 2021), $87000.0 (Q2 2021), and $96000.0 (Q1 2021) per Business Quant data.